Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

4_4 Jun. 27 at 5:16 PM

$OLMA Buyout for Palazestrant would be nice. $NVS ? Probably jumping to conclusions before PFS info is out.

0 · Reply

justiceforb_85 Jun. 26 at 8:11 PM

$OLMA look forward to future updates of palazestrant.

0 · Reply

StardustTrader Jun. 17 at 9:41 PM

$OLMA adding a bit more

0 · Reply

JimCramerisadoofus Jun. 12 at 1:36 PM

$OLMA Buy the dip!

0 · Reply

StardustTrader Jun. 10 at 4:36 PM

$OLMA this is the zone. Averaging up a smidge.

0 · Reply

JimCramerisadoofus Jun. 4 at 2:24 PM

$OLMA This company has no debt. Five analysts rate as BUY Three analysts rate as STRONG BUY 95% of shares are owned by institutions Strong pipeline of candidates to treat endocrine driven cancers. I’m in at $4.00

0 · Reply

djgestates Jun. 4 at 11:21 AM

$OLMA

0 · Reply

Zeekola Jun. 3 at 8:37 PM

$OLMA

0 · Reply

valueinvestor1998 Jun. 2 at 10:45 PM

$OLMA did they present poor data at ASCO?

4 · Reply

jgodski Jun. 2 at 6:49 PM

$OLMA Any ideas why the selloff today other than some profit taking, maybe short selling to anticipate or drive a drop after recent news? I'm just in at $4.40.

0 · Reply

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 7:00 AM EDT - 4 weeks ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 21, 2025, 4:30 PM EDT - 5 weeks ago

Olema Oncology to Participate in Upcoming Investor Conferences

May 13, 2025, 4:01 PM EDT - 6 weeks ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 2 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 2 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 3 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 3 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 4 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 6 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 6 months ago

Top 3 Health Care Stocks That May Explode In Q4

MODV SLN

Dec 10, 2024, 7:00 AM EST - 7 months ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 7 months ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 7 months ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 8 months ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 8 months ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 9 months ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 11 months ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 11 months ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 1 year ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 1 year ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 1 year ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 1 year ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 1 year ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 1 year ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 1 year ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Oct 16, 2023, 7:02 AM EDT - 1 year ago

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oct 12, 2023, 7:01 AM EDT - 1 year ago

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Sep 20, 2023, 7:29 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 3:20 PM EDT - 1 year ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Olema Oncology Announces Combined Financing for Up to $180 Million

Aug 8, 2023, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

May 30, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

May 19, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology: Best Contrarian Oncology Play For 2023

May 11, 2023, 8:43 AM EDT - 2 years ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

May 9, 2023, 4:01 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023, 7:06 AM EDT - 2 years ago

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

Apr 13, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

4_4 Jun. 27 at 5:16 PM

$OLMA Buyout for Palazestrant would be nice. $NVS ? Probably jumping to conclusions before PFS info is out.

0 · Reply

justiceforb_85 Jun. 26 at 8:11 PM

$OLMA look forward to future updates of palazestrant.

0 · Reply

StardustTrader Jun. 17 at 9:41 PM

$OLMA adding a bit more

0 · Reply

JimCramerisadoofus Jun. 12 at 1:36 PM

$OLMA Buy the dip!

0 · Reply

StardustTrader Jun. 10 at 4:36 PM

$OLMA this is the zone. Averaging up a smidge.

0 · Reply

JimCramerisadoofus Jun. 4 at 2:24 PM

0 · Reply

djgestates Jun. 4 at 11:21 AM

$OLMA

0 · Reply

Zeekola Jun. 3 at 8:37 PM

$OLMA

0 · Reply

valueinvestor1998 Jun. 2 at 10:45 PM

$OLMA did they present poor data at ASCO?

4 · Reply

jgodski Jun. 2 at 6:49 PM

$OLMA Any ideas why the selloff today other than some profit taking, maybe short selling to anticipate or drive a drop after recent news? I'm just in at $4.40.

0 · Reply

valueinvestor1998 Jun. 2 at 4:13 AM

$OLMA should have picked it up at $3 😢

0 · Reply

spider521 May. 31 at 1:25 PM

$OLMA Analysts have set price targets range from a low of $18 to a high of $30, showing strong confidence in the company's future prospects.

0 · Reply

spider521 May. 31 at 1:24 PM

$OLMA Olema Pharmaceuticals will present at two major healthcare conferences in June 2025: Jefferies Global Healthcare Conference: June 4, 2025, at 11:40 a.m. ET in New York, in a fireside chat format. Goldman Sachs 46th Annual Global Healthcare Conference: June 11, 2025, at 8:00 a.m. ET in Miami, also as a fireside chat.

0 · Reply

StardustTrader May. 28 at 5:12 PM

$OLMA very possibly reversing here. Will add if we retest 3s/ low 4s.

0 · Reply

CosmicCato May. 26 at 3:08 AM

$BOLD should have a big run like $OLMA did from Jan 2023 to late 2024. BOLD has more cash and book value per share, not to mention the recent Buy rating and trial results coming.

0 · Reply

spider521 May. 23 at 3:26 PM

$OLMA extreme bullish for this company https://www.nasdaq.com/articles/wall-street-analysts-see-38642-upside-olema-pharmaceuticals-olma-can-stock-really-move

0 · Reply

AnomalyDetective May. 21 at 12:38 PM

The Top Breakout blog releasing free picks from automated algorithm like $OLMA and many others throughout the week. https://top.vmbreakouts.com/olma-19-pick/?ref=v-m-breakouts-newsletter

0 · Reply

JarvisFlow May. 14 at 3:07 PM

Goldman Sachs has adjusted their stance on Olema Pharmaceuticals ( $OLMA ), setting the rating to Buy with a target price of 20 → 18.

0 · Reply

spider521 May. 13 at 8:39 PM

$OLMA Q1 EPS $(0.36) Beats $(0.51) Estimate

0 · Reply

Armonica423 May. 10 at 4:52 PM

$OLMA big week coming up for CYDY, tons of exposure at cancer conferences, time to do your dd research,

0 · Reply

spider521 May. 9 at 9:49 PM

$OLMA They will participate in two major investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, in New York. T.D. Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, in a virtual format. Both will be fireside chats, with webcasts available on Olema’s investor relations site

0 · Reply

spider521 May. 5 at 12:12 PM

$OLMA https://www.marketbeat.com/instant-alerts/renaissance-technologies-llc-has-917000-stock-holdings-in-olema-pharmaceuticals-inc-nasdaqolma-2025-05-01/

0 · Reply

Market Cap	316.11M
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,459,000
Avg Vol	871,358
Day's Range	N/A - N/A
Shares Out	68.42M
Stochastic %K	80%
Beta	1.99
Analysts	Strong Sell
Price Target	$24.71